ArticleSTAR protocols2026
Protocol for quantifying the oxidative cleavage of amyloid-β using oxygen-18 isotope labeling and LC-MS/MS.
Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we present a protocol for quantifying the oxidative cleavage of amyloid-β using oxygen-18 labeling coupled with high-resolution LC-MS/MS. We describe procedures for amyloid-β peptide preparation, copper(II)/ascorbate-mediated oxidative cleavage, oxygen-18 incorporation, LC-MS/MS acquisition, and isotopologue-based quantitative data analysis. By incorporating oxygen-18 into newly generated C-termini during metal-driven cleavage and applying defined isotope conditions, this protocol enables site-specific identification of true cleavage-derived fragments while discriminating them from background signals arising from natural isotopic overlap and pre-existing impurities. This strategy supports confident identification of oxidative cleavage products and can be adapted to studies of peptide degradation in related systems. For complete details on the use and execution of this protocol, please refer to Yang et al.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.